Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04041479 · ClinicalTrials.gov registry record · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
A Phase 3 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
- 2
- Study locations
NCT04041479: Recruiting Phase 3 study of Major Depressive Disorder and Treatment-Resistant Depression, sponsored by Weill Medical College of Cornell University.
NCT04041479 is a Phase 3 study of Major Depressive Disorder and Treatment-Resistant Depression that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 348 participants, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04041479, a Phase 3 study of Major Depressive Disorder and Treatment-Resistant Depression, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
- 2
- Study locations
Study Summary
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research project is to use brain network connectivity patterns as measured by resting state functional magnetic resonance imaging (fMRI) to confirm a way to optimize the use of rTMS to treat depression. In addition, the study aims to gain a better understanding of how rTMS influences brain networks.
Primary Outcome
The Hamilton Depression Rating Scale (HAMD17) is a 17 item clinician-rated measure of depression severity. Scores of 0-7 = Normal, 8-13 = Mild Depression, 14-18 = Moderate Depression, 19-22 = Severe Depression, ≥ 23 = Very Severe Depression
Conditions Studied
Interventions
- DEVICE Repetitive Transcranial Magnetic Stimulation
Study Locations (2)
California
- Stanford University - Stanford
New York
- Weill Cornell Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
What NCT04041479 shows while recruiting
NCT04041479 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target.
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Repetitive Transcranial Magnetic Stimulation is the first listed.
NCT04041479 reports a single indexed study location in California, New York.
Frequently Asked Questions
What is clinical trial NCT04041479 about?
NCT04041479 is a clinical study titled "Biomarker-guided rTMS for Treatment Resistant Depression". Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment. The purpose of this research project is to use brain network connectivity patterns as measured by resting state functional magnet...
What is the current status of trial NCT04041479?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2021-09-17. Estimated completion is 2027-08.
What conditions does trial NCT04041479 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Treatment-Resistant Depression.
What interventions are being tested in trial NCT04041479?
The interventions under investigation include: Repetitive Transcranial Magnetic Stimulation (DEVICE).
Who is sponsoring clinical trial NCT04041479?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04041479 being conducted?
This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04041479's enrollment target sits among peer trials
348 48th of 282 higher than 235 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
Study to Assess the Safety and Effectiveness of NMRA-335140-501
RECRUITING · Phase 3
-
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
-
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
RECRUITING · Phase 3
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
RECRUITING · Phase 3
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05428735 · 348 participants · NA
The DRAGON 2 Trial
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
- NCT05815784 · 348 participants · Phase 2
Myopia Control: a Comparison Study Between Atropine and MiSight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI